Meeting Minutes: Drug Formulary Committee

Date & Time: August 13, 2019; 5:30-9 PM
Minutes prepared by: Umang Patel and Dave Hoang
Location: Elmer Andersen Building, Room 2370, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members in attendance: Margaret Artz, RPh., PhD.; Kyle Lehenbauer, MD.; Kathryn Lombardo, MD.; Stacey Ness, PharmD.; James Phillips, MD.; Kelly Ruby, PharmD.; Stuart Williams, J.D.; Mary Mescher Benbenek, APRN, PhD.; Ramona Powell, PharmD.; Monica Brands, RPh.
- Member absent: Al Heaton, PharmD.; Michael Sprehe, MD.
- DHS staff present: Dave Hoang, PharmD., MBA; Chad Hope, PharmD; Sharon Feinstein-Rosenblum, PharmD; Seojung Kang, Pharmacy Student
- Others in attendance: Umang Patel, PharmD.; Ariane Casey, PharmD.

Report of the Chair

- No report from the Chair.

Approval of Minutes

- Minutes from the July 2019 meeting were reviewed and approved.

DHS Housekeeping

- Uniform PDL implementation update

Old Business

Existing Specialty Drugs for Continued PA

- The committee discussed Diclegis and Bonjesta and recommended to the department by a unanimous vote that Diclegis and Bonjesta remain on PA, with the following revision:
  - Addition of a doxylamine sub-bullet in the 7th bullet
  - Open access coverage to at least 1 rebateable doxylamine NDC, if available
New Business

New Specialty Drugs for Continued PA

- The committee recommended to the department by a unanimous vote that the review of Zolgensma be postponed in light of the FDA’s statement on Zolgenma manufacturer’s data manipulation during its clinical trials.

- The committee discussed Lumoxiti and recommended to the department by a unanimous vote that Lumoxiti remain on PA.

- The committee discussed Revcovi and recommended to the department by a unanimous vote that Recovi remain on PA.

- The committee discussed Krintafel and recommended to the department by a unanimous vote that Krintafel remain on PA.

- The committee discussed Yutiq and recommended to the department by a unanimous vote that Yutiq remain on PA, with the following revision:
  - Addition of the following criterion in the Initial Approval Criteria: “Prescriber documents patient has not previously received Yutiq”
  - Addition of the following criterion in the Initial Approval Criteria: “Patient must not be on concurrent Humira or any other biologics for uveitis”
  - Addition of the following criterion in the Renewal Criteria: “Prescriber documents patient has received Yutiq previously, along with the date(s) of use”

- The committee discussed Qbrexa and recommended to the department by a unanimous vote that Qbrexa remain on PA

- The committee discussed Spravato and recommended to the department by a unanimous vote that Spravato remain on PA, with the following revision:
  - Remove “or prior” in the 5th bullet
  - Remove the 4th and the 6th sub-bullets of the 5th bullet
  - In the 5th sub-bullet of the 5th bullet, replace “History of” with “Active or recent”
  - Remove “Patient must not have intellectual disability”
  - Remove 9th bullet
  - In the 12th bullet, add the sub-bullet: “Cytomel, OR”
  - Remove 15th bullet

- The committee discussed Balversa and recommended to the department by a unanimous vote that Balversa remain on PA, with the following revision:
  - Add “or FGFR-2” in the third bullet
• The committee discussed Skyrizi and recommended to the department by a unanimous vote that Skyrizi remain on PA.

• The committee discussed Vyndaqel and Vyndamax and recommended to the department by a unanimous vote that Vyndaqel and Vyndamax remain on PA.

Preferred Drug List Review

1. Antidepressant
   a. Spravato: The committee discussed Spravato and recommended to the department by a unanimous vote that Spravato be nonpreferred.

2. Immunomodulators
   a. Skyrizi: The committee discussed Skyrizi and recommended to the department by a unanimous vote that Skyrizi be nonpreferred (tier 3).

Adjournment

• The meeting was adjourned at approximately 8:50 PM Central Time.